News

Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results
Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...
Managed Healthcare Executive1d
Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
Applied Clinical Trials Online12d
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
PharmExec12d
Pfizer’s Hympavzi Demonstartes Significantly Reduced Annualized Bleeding Rates in Hemophilia
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
Pfizer’s HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
Fierce Pharma13d
Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
The Pharma Letter13d
Pfizer releases positive Hympavzi Phase III results in hemophilia
US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi ...
Pfizer's Hympavzi Hits Key Goals in Hemophilia With Inhibitors
Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.
Morningstar13d
Pfizer's Hympavzi Hits Key Goals in Hemophilia With Inhibitors
Pfizer on Thursday said the Phase 3 study of Hympavzi in patients 12 and older with hemophilia A or B with inhibitors met its primary endpoint and key secondary bleeding endpoints, showing a ...